Details for New Drug Application (NDA): 206939
✉ Email this page to a colleague
NDA 206939 describes CEFIXIME, which is a drug marketed by Alkem Labs Ltd, Aurobindo Pharma Ltd, Belcher, and Chartwell Rx, and is included in six NDAs. It is available from five suppliers. Additional details are available on the CEFIXIME profile page.
The generic ingredient in CEFIXIME is cefixime. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cefixime profile page.
The generic ingredient in CEFIXIME is cefixime. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cefixime profile page.
Medical Subject Heading (MeSH) Categories for 206939
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 500MG/5ML | ||||
| Approval Date: | Feb 6, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
